BeiGene

BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

SAN DIEGO , Dec. 8, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced a clinical supply agreement with BeiGene, Ltd. (NASDAQ: BGNE) to evaluate the safety and efficacy of Phanes' PT199, a differentiated anti-CD73 monoclonal antibody in combination with BeiGene's tislelizumab, an anti-PD-1 monoclonal antibody in the Phase I clinical study  (NCT05431270) for the treatment of multiple advanced solid tumors.

Phanes Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate PT199 in combination with Tislelizumab

The Chinese pharmaceutical stock is experiencing a comeback.

Why Shares of BeiGene Were Up Wednesday

Bio-Rad Laboratories

Catalent

DexCom

Edwards Lifesciences

Gilead Sciences

Intuitive Surgical

Moderna

Seagen

West Pharmaceutical Services

The healthcare sector has gained momentum following the COVID-19 pandemic. Several companies gained early regulatory approval for developing COVID-19 drugs and distributing vaccines.

These Are the Five Best and Worst Performing Healthcare Stocks in October 2022

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--( BUSINESS WIRE )--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) a global biotechnology company, today announced that the results of the final progression free survival (PFS) analysis of the ALPINE trial will be presented at a late-breaking oral presentation session at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans. ALPINE is a global Phase 3 trial comparing BRUKINSA (zanubrutinib) with IMBRUVICA® (ibrutinib) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). The results will be presented at 10:15 am CST during the late-breaking abstract session on Tuesday, December 13, 2022 in the Ernest N. Morial Convention Center, Hall E.

BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--( BUSINESS WIRE )--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the European Commission (EC) has approved BRUKINSA ® (zanubrutinib) for the treatment of adult patients with treatment-naïve (TN) or relapsed/refractory (R/R) CLL.

BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--( BUSINESS WIRE )--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the launch of a new program, Talk About It: Cancer and Mental Health, designed to elevate the important intersection of mental health and cancer care to help improve health outcomes for cancer patients.

BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care

BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers

BeiGene Reports Third Quarter 2022 Financial Results

BeiGene's shares are down this year, but it has two potential blockbusters.

Is This Chinese Pharmaceutical Stock Worth the Risk?

BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting

BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma

BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL

BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average.

BeiGene, Ltd. (BGNE) Soars 20.6%: Is Further Upside Left in the Stock?

BeiGene stock popped Wednesday after the company's leukemia treatment beat out a blockbuster drug from Johnson & Johnson. The post BeiGene Takes On Johnson & Johnson's Blockbuster Cancer Drug — And Wins appeared first on Investor's Business Daily.

BeiGene Takes On Johnson & Johnson's Blockbuster Cancer Drug — And Wins

BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® (zanubrutinib) Compared to IMBRUVICA® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial

These articles are intended to provide readers with equity investment subjects [stocks, ETFs, REITs] which probably may experience rising market prices in next 3-5 months: Near-term expectations only. They are drawn from a 3,000+ equity population updated daily which infers “Institutional” [big$] investor coming-price expectations from recent-past volume block-trade orders facilitated by Market-Makers.

BeiGene: Best Biotech Industry Stock Bet Say Portfolio Wealth Builders

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company that is developing and commercializing oncology medicines, today announced that England's health technology assessment institute, the National Institute for Health and Care Excellence (NICE), has issued a final appraisal document (FAD) recommending BRUKINSA (zanubrutinib) for the treatment of Waldenström's Macroglobulinemia (WM) in adults who have ha

NICE Recommends BeiGene's BRUKINSA® (zanubrutinib) for Patients with Waldenström's Macroglobulinemia who have had at Least One Treatment

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of BRUKINSA ® (zanubrutinib) for the treatment of

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, shared updates from its solid tumor development program for cornerstone PD-1 antibody tislelizumab at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris. Results from the Phase 3 RATIONALE 301

BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Company will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th, 2022 with a fireside chat at 9:10 a.m. ET. A live webcast

BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Hutchison China MediTech Ltd.

JD.com

Ping An Insurance Group Co of China Ltd

China Rapid Finance

Tencent Holdings Limited

Considering the slowdown in the world's second-largest economy, it's probably the right time to think about some Chinese stocks to sell. China barely escaped contraction during the second quarter as consumer and manufacturing activity slowed down in the face of repeated lockdowns.

7 Chinese Stocks to Sell While You Still Can

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental biologics license application (sBLA) for tislelizumab

BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide, today announced a strategic agreement with Ontada®, a McKesson business with leading provider technology and actionable real-world research, education, and evidence in oncology, to improve U.S.

BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care

CAMBRIDGE, U.S. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the global Phase 3 RATIONALE 301 trial with tislelizumab met its primary endpoint of non-inferior Overall Survival (OS) versus sorafenib as a first-line treatment in adult patients with unresectable h

BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer

News for BeiGene Stock (BGNE)